These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29385878)

  • 41. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
    Khalaf DJ; Sunderland K; Eigl BJ; Kollmannsberger CK; Ivanov N; Finch DL; Oja C; Vergidis J; Zulfiqar M; Gleave ME; Chi KN
    Eur Urol; 2019 Jun; 75(6):940-947. PubMed ID: 30591354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis.
    Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
    J Clin Pharm Ther; 2020 Jun; 45(3):488-495. PubMed ID: 31951037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
    Shao N; Zhu Y; Ye DW
    Eur Urol Focus; 2019 Sep; 5(5):745-747. PubMed ID: 30797739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
    Murga JD; Moorji SM; Han AQ; Magargal WW; DiPippo VA; Olson WC
    Prostate; 2015 Feb; 75(3):242-54. PubMed ID: 25327687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
    Shiota M; Kashiwagi E; Murakami T; Takeuchi A; Imada K; Inokuchi J; Tatsugami K; Eto M
    Urol Oncol; 2019 Mar; 37(3):180.e19-180.e24. PubMed ID: 30446464
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
    Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO
    Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
    Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.
    Iguchi T; Tamada S; Kato M; Yasuda S; Otoshi T; Hamada K; Yamasaki T; Nakatani T
    Int J Clin Oncol; 2019 Jul; 24(7):848-856. PubMed ID: 30741370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.
    Maughan BL; Guedes LB; Boucher K; Rajoria G; Liu Z; Klimek S; Zoino R; Antonarakis ES; Lotan TL
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):260-268. PubMed ID: 29302046
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
    Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
    Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks.
    Lieberman R
    Am J Ther; 2013; 20(2):128-31. PubMed ID: 23466618
    [No Abstract]   [Full Text] [Related]  

  • 54. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer.
    Uchimoto T; Komura K; Fujiwara Y; Saito K; Tanda N; Matsunaga T; Ichihashi A; Tsutsumi T; Tsujino T; Yoshikawa Y; Nishimoto Y; Takai T; Minami K; Taniguchi K; Tanaka T; Uehara H; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Azuma H
    Med Oncol; 2019 Nov; 37(1):9. PubMed ID: 31754918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
    Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
    Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
    Arslan C
    World J Urol; 2017 Mar; 35(3):479-480. PubMed ID: 27417948
    [No Abstract]   [Full Text] [Related]  

  • 59. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D;
    N Engl J Med; 2019 Dec; 381(26):2506-2518. PubMed ID: 31566937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
    Tombal B
    Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.